Daniel Lee, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Laura Bamford, MD, MSCE
Associate Professor of Medicine
Medical Director, Owen Clinic
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
Jocelyn Keehner, MD
Infectious Disease Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Elliot Welford, MD
Infectious Diseases Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Leandro Mena, MD, MPH
Chair and Professor of Population Health Science
Department of Population Health Science
University of Mississippi Medical Center
Daniel Lee, MD
Clinical Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Laura Bamford, MD, MSCE
Associate Professor of Medicine
Medical Director, Owen Clinic
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
Jocelyn Keehner, MD
Infectious Disease Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Elliot Welford, MD
Infectious Diseases Fellow
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Leandro Mena, MD, MPH
Chair and Professor of Population Health Science
Department of Population Health Science
University of Mississippi Medical Center
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Winston Tilghman, MD
Medical Director, STD Controller
HIV, STD & Hepatitis Branch of Public Health Services
County of San Diego Health & Human Services Agency
Edward Cachay, MD, MAS
Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Current epidemiology of meningococcal disease in the African meningitis belt and new WHO outbreak response guidelines after the Meningitis Vaccine Project
http://www.meningitis.org/conference2015
Video Directly Observed Therapy for HIV and TB patientsKimberly Schafer
Video-Directly Observed Therapy (V-DOT) is a promising solution for monitoring TB and HIV
treatment adherence for binational patients in the U.S.-Mexico border region.
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Winston Tilghman, MD
Medical Director, STD Controller
HIV, STD & Hepatitis Branch of Public Health Services
County of San Diego Health & Human Services Agency
Edward Cachay, MD, MAS
Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Current epidemiology of meningococcal disease in the African meningitis belt and new WHO outbreak response guidelines after the Meningitis Vaccine Project
http://www.meningitis.org/conference2015
Video Directly Observed Therapy for HIV and TB patientsKimberly Schafer
Video-Directly Observed Therapy (V-DOT) is a promising solution for monitoring TB and HIV
treatment adherence for binational patients in the U.S.-Mexico border region.
Outline:
Introduction
Epidemiologic Determinants
Mode of transmission
Burden of Hepatitis-B
Prevention and treatment
Challenges
Recent Advances in Hepatitis B research
Strategies
References
There are nearly 100 viruses of the herpes group that infect many different animal species.
Official name of herpesviruses that commonly infect human is Humans herpesvirus (HHV)
herpes simplex virus types 1 (HHV 1)
Herpes simplex virus type 2 (HHV 2)
Varicella-zoster virus (HHV 3)
Epstein-Barr virus, (HHV 4)
Cytomegalovirus (HHV 5)
Human herpesvirus 6 (HHV 6)
Human herpesvirus 7 (HHV 7)
Human herpesvirus 8 (HHV 8) (Kaposi's sarcoma-associated herpesvirus).
Herpes B virus of monkeys can also infect humans
hELMINTHS#corona virus#Aspergillosis#BUGANDO#CUHAS#CUHAS#CUHAS#HEPATITIS MADE EASY#HEPATITS B#HEPATITIS C#
This lecture describes the approach to screening, diagnosis and management of HIV and TB infection among pregnant patients. Prevention of Mother to Child Transmission of HIV infection mainly based on the Philippine Obstetrical and Gynecological Society Clinical Practice Recommendations.
Preventing type 2 diabetes in england, pop up uni, 2pm, 2 september 2015NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
3. HB Control Targets
Hepatitis B is a priority
•
In 2005, countries in the Western Pacific Region including
the Philippines aimed to:
Milestone : Reduce the prevalence of chronic HBV
infection to <2% among children aged ≥5 years by 2012
Goal: Reduce the prevalence to ≤ 1% among children ≥5
years by 2017
4. Strategies to Achieve the Goal
• High coverage of 3 doses of hepatitis B vaccine (HepB3),
with a birth dose given within 24 hours of birth
• Measuring the prevalence of chronic HBV infection by
conducting representative seroprevalence surveys;
• Verifying achievement of a reduced prevalence of chronic
HBV infection by submitting country-level data to be
reviewed by a regional verification panel.
5. Strategy 1: Hepatitis B vaccination
• ≥65% timely birth dose coverage defined as within 24H
after birth
• ≥ 85% three (3) dose of Hepatitis B vaccine coverage
6. Immunization Schedule for Infants
AGE
Antigen
At birth 1 ½ mo
BCG
3 ½ mo
9mo
12mo
√
HepB
2 ½ mo
√
DPT-HepB-Hib
√
√
√
OPV
√
√
√
Rota
√
√
Measles
MMR
√
√
9. WHAT HAS BEEN DONE?
…..Hepatitis B immunization
in the PhilHealth Newborn
Package…
Time Band:
90minutes to 6hrs
Intervention:
Inject HepB and BCG
10. Strategy 2: Measure Impact-1
• Field assessment of the hepatitis b birth dose practices in health
facilities in 2011
• Done in 8/17 regions in the country
• 142 health facilities were assessed (health centers , lying-in
clinics, public & private hospitals with deliveries)
11.
12. Strategy 2: Measure Impact-2
• National Hepatitis B Seroprevalence Study in 2013
• 1st Hepatitis B seroprevalence survey conducted in the Philippines
among children
• Objectives
• Primary: To determine the seroprevalence of HBsAg among 5-6
year old children.
• Secondary: To evaluate the HepB vaccination effectiveness by
reviewing the HepB vaccination coverage including timing of the
first dose along with the seroprevalence of HBsAg in the sampled
population
13. Strategy 2: Measure Impact-2
• National Hepatitis B Seroprevalence Study in 2013
• Sample population were children born between
January 1, 2007- December 31, 2008
• 3000 children aged 5-6 years old
•
• RESULT will be available SOON……
14. Strategy 3: Verification of Reduced
Prevalence of chronic Hep B Infection
• Country notify WHO readiness for the verification process
• Submits evidences that the prevalence of chronic hepatitis
reduced.
15. HBV prevalence among blood donors and
OFWCs* (2002-2004)
HBsAg
Number
Tested
Number
positive
%
Blood Donors
Male
59,740
2,551
4.27
5,214
153
2.93
64,954
2,704
4.16
Male
30,484
1,374
4.51
Female
49,186
1,952
3.97
All
79,670
3,326
4.17
Female
All
OFWs
* Yanase, Gill, et. al
16. HBsAg positivity rates among clients of Laboratories
Participating in EQAS of NRL – SACCL
(2010-2012)
Year
2012
2011
2010
HBV Total
Tested
HBV(+)
%+
#lab
2,206,310 99,184
4.49
1019
1,936,046 97,814
5.05
789
1,712,645 90,052
5.25
429
Census of Natioanl Reference Lab – STD AIDS Cooperative Laboratory
17. What has been done. . .
Guidelines for the Implementation of a Workplace
Policy and Program on Hepatitis B (DOLE)
All establishments are encouraged to provide mandatory HepB
vaccination to employees
– Required for healthcare workers and high-risk individuals
• Individuals with HepB should not be declared unfit to work without
medical evaluation, nor terminated on the basis of HepB status
• confidentiality, referral system in the workplace
• Screening for HepB as pre-requisite for employment shall not be
mandatory
• Those who contract HepB in the course of their duty are entitled of
Health benefits under SSS and Employees Compensation Benefits
under PD 626
• IEC on hepatitis
https://dl.dropbox.com/u/84112124/Department%2520Advisory%2520No.
%252005%2520%28Corrected%2520Copy%29%5B1%5D.pdf
18. What has been done. . .
• Policy on Post Exposure Management
(PEM) for HIV, Hepatitis B & C in
Healthcare Settings (DOH) – Technical
Guide
• All hospitals shall include Hepatitis B and C into existing HIV
awareness campaign by HACT or ICC
• New entrant health care personnel in clinical and ancillary
departments shall be required to undergo mandatory Hep B
vaccination
• All cases of accidental exposures should be reported to ICC
for a decision to commence PEP
19. • Policy on Post Exposure Management (PEM) for
HIV, Hepatitis B & C in Healthcare Settings
20. •
What has been done. . .
• Guidelines and packages which help assist service
providers and managers including safety, quality
and availability of blood are available
• Infection control guideline -prevention of hepa B
and other diseases in the health care setting
• Persons with active chronic Hep B and HIV can
now benefit new treatment with anti-retrovirals
23. Action Points
• Increase awareness and knowledge on hepatitis
including that of health care workers integrated
with other health promotion activities
• Enhance Planning and working with partners
24. •
Challenges
• surveillance systems for HepB – basis for
evidence-based policy actions
• People Who Inject Drugs - horizontal and vertical
transmission
• Many chronically infected individuals are unaware
of their Hep B status
• Behavior change
25.
26.
27.
28.
29.
30. Support Healthy Lifestyle Programs
•Enforce restrictions on smoking in public places and near schools based on the Tobacco
Regulations Act
•Enforce restrictions on selling tobacco products based on the Tobacco Regulations Act
• Grant access to lands that the community can use as pocket farms to grow fruits and
vegetables
• Hold community feeding programs to teach children the value of nutritious food
• Hold lectures for mothers to teach them how to prepare healthy yet inexpensive food
• Provide courts and facilities that can serve as venue for physical activities
• Host sports fests that will foster healthy competition and sportsmanship
• Hold a community exercise program to in partnership with local gym or fitness center
instructors?
• Enforce restrictions on selling alcohol to minors
Read Slide ,,,,
Presentation focus on the primary hepatitis b immunization during infancy.
Hepatitis B vaccine introduced in the Philippines in 1992 in a phased manner.
Nationwide implementation of the Hepatitis B vaccination achieved in 2006
Birth dose incorporated in the country’s Expanded Programme of Immunization (EPI) in 2007.
Since 2007, this has been the current immunization schedule for infants. For hepatitis b vaccination, an infant will receive 4 doses of hepatitis b vaccines, at birth with the monovalent vaccine and additional 3 doses at 1.5 months , 2.5 months and 3.5 months. All EPI vaccines are procured by the government. And all vaccines procured are WHO pre=qualified.
This is the current immunization schedule for Infants. The monovalent Hepatitis B vaccination is given at birth within 24 hours after birth, and the combination DPT-HepB-Hib (known us Pentavalent vaccine) is given at 6W, 10W and 14W. Therefore, an infant should receive a total of 4 doses of Hepatitis B before reaching 1 year old.
Ay sori…senior moments. Monovalent HepB only for HepB birth dose (HepB BD). Pentavalent vaccines refers to DPT-HepB-Hepatitis B vaccines. So an infant will receive a total of 4 doses of HepB (Birth Dose, 3 penta at 6W, 10W, 14W).
Vaccines are procured by national and distributed nationwide. Vaccination is free of charge.
Maam di ko ma-update.
2011 hepb birth dose 42 % ;hepb3 80%
2012 birthdose 35, hepb3 70%. Stock-out of hepb vaccine
Republic Act No. 10152 has been signed. It is otherwise known as the “Mandatory Infants and Children Health Immunization Act of 2011, which requires that all children under five years old be given basic immunization against vaccine-preventable diseases. Specifically, this bill provides for all infants to be given the birth dose of the Hepatitis-B vaccine within 24 hours of birth.
In the Philippines one strategy to strengthen Hepatitis B coverage, administration of birth dose is integration of Hep B birth dose administration in the Essential Intrapartum and Newborn Care Package (EINC). In 2011 11 tertiary hospitals are already EINC compliant. And
In the inclusion of the hepatitis B immunization in the Philhealth’s insurance newborn package.
Sample selection: 3-stage cluster used probability proportional to size calculation
First stage is province – 25 provinces or highly urbanized centers chosen using probability-proportional-to-size-sampling (PPS)
Second stage is barangay - Within each province, 12 barangays
Third stage is children - Within each barangay, 10 children born in 2007-8